Advertisement

Toward Clinical Translation of Neuroimaging Research in Schizophrenia and Other Primary Psychotic Disorders

  • Annarita Vignapiano
  • Lynn E. DeLisi
  • Silvana Galderisi
Chapter

Abstract

Recently, neuroimaging research has substantially increased our understanding of the pathophysiology of psychotic disorders by detailing their association with distributed, complex, multimodal patterns of brain aberrations. Several studies have reported differences between subjects with psychotic disorders and healthy controls in structural, functional, and neurochemical neuroimaging measures. However, the clinical utility of these findings is not yet clear.

This chapter will focus on the ability of neuroimaging biomarkers to be used in the early diagnosis and prediction of treatment response. In addition, although the majority of neuroimaging studies reported differences at the group level, we will discuss the importance of moving from group differences to the individual, in order to translate research findings into routine clinical practice. Machine learning, using a multivariate approach, could represent a promising method with a potential for translation into psychiatric clinical practice.

References

  1. 1.
    Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69(3):89–95.  https://doi.org/10.1067/mcp.2001.113989.CrossRefGoogle Scholar
  2. 2.
    Galderisi S. Current trends in diagnosis and treatment of mental disorders. Eur Psychiatry. 2018;50:4–6.  https://doi.org/10.1016/j.eurpsy.2017.11.008.CrossRefPubMedGoogle Scholar
  3. 3.
    Cuthbert BN, Kozak MJ. Constructing constructs for psychopathology: the NIMH research domain criteria. J Abnorm Psychol. 2013;122(3):928–37.  https://doi.org/10.1037/a0034028.CrossRefPubMedGoogle Scholar
  4. 4.
    Morris SE, Cuthbert BN. Research Domain Criteria: cognitive systems, neural circuits, and dimensions of behavior. Dialogues Clin Neurosci. 2012;14(1):29–37.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Cuthbert BN. The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology. World Psychiatry. 2014;13(1):28–35.  https://doi.org/10.1002/wps.20087.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Abi-Dargham A, Horga G. The search for imaging biomarkers in psychiatric disorders. Nat Med. 2016;22(11):1248–55.  https://doi.org/10.1038/nm.4190.CrossRefPubMedGoogle Scholar
  7. 7.
    Fu CH, Costafreda SG. Neuroimaging-based biomarkers in psychiatry: clinical opportunities of a paradigm shift. Can J Psychiatry. 2013;58(9):499–508.  https://doi.org/10.1177/070674371305800904.CrossRefPubMedGoogle Scholar
  8. 8.
    McGuire P, Sato JR, Mechelli A, Jackowski A, Bressan RA, Zugman A. Can neuroimaging be used to predict the onset of psychosis? Lancet Psychiatry. 2015;2(12):1117–22.  https://doi.org/10.1016/S2215-0366(15)00308-9.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Borgwardt S, Schmidt A. Implementing magnetic resonance imaging into clinical routine screening in patients with psychosis? Br J Psychiatry. 2017;211(4):192–3.  https://doi.org/10.1192/bjp.bp.117.199919.CrossRefPubMedGoogle Scholar
  10. 10.
    Kempton MJ, Stahl D, Williams SC, DeLisi LE. Progressive lateral ventricular enlargement in schizophrenia: a meta-analysis of longitudinal MRI studies. Schizophr Res. 2010;120(1–3):54–62.  https://doi.org/10.1016/j.schres.2010.03.036.CrossRefPubMedGoogle Scholar
  11. 11.
    Haijma SV, Van Haren N, Cahn W, Koolschijn PC, Hulshoff Pol HE, Kahn RS. Brain volumes in schizophrenia: a meta-analysis in over 18,000 subjects. Schizophr Bull. 2013;39(5):1129–38.  https://doi.org/10.1093/schbul/sbs118.CrossRefPubMedGoogle Scholar
  12. 12.
    van Erp TG, Hibar DP, Rasmussen JM, Glahn DC, Pearlson GD, Andreassen OA, Agartz I, Westlye LT, Haukvik UK, Dale AM, Melle I, Hartberg CB, Gruber O, Kraemer B, Zilles D, Donohoe G, Kelly S, McDonald C, Morris DW, Cannon DM, Corvin A, Machielsen MW, Koenders L, de Haan L, Veltman DJ, Satterthwaite TD, Wolf DH, Gur RC, Gur RE, Potkin SG, Mathalon DH, Mueller BA, Preda A, Macciardi F, Ehrlich S, Walton E, Hass J, Calhoun VD, Bockholt HJ, Sponheim SR, Shoemaker JM, van Haren NE, Pol HE, Ophoff RA, Kahn RS, Roiz-Santianez R, Crespo-Facorro B, Wang L, Alpert KI, Jonsson EG, Dimitrova R, Bois C, Whalley HC, McIntosh AM, Lawrie SM, Hashimoto R, Thompson PM, Turner JA. Subcortical brain volume abnormalities in 2028 individuals with schizophrenia and 2540 healthy controls via the ENIGMA consortium. Mol Psychiatry. 2016;21(4):585.  https://doi.org/10.1038/mp.2015.118.CrossRefPubMedGoogle Scholar
  13. 13.
    Hager BM, Keshavan MS. Neuroimaging biomarkers for psychosis. Curr Behav Neurosci Rep. 2015;2015:1–10.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S. Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev. 2013;37(8):1680–91.  https://doi.org/10.1016/j.neubiorev.2013.06.001.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Fusar-Poli P, Radua J, McGuire P, Borgwardt S. Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies. Schizophr Bull. 2012;38(6):1297–307.  https://doi.org/10.1093/schbul/sbr134.CrossRefPubMedGoogle Scholar
  16. 16.
    Mathew I, Gardin TM, Tandon N, Eack S, Francis AN, Seidman LJ, Clementz B, Pearlson GD, Sweeney JA, Tamminga CA, Keshavan MS. Medial temporal lobe structures and hippocampal subfields in psychotic disorders: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. JAMA Psychiatry. 2014;71(7):769–77.  https://doi.org/10.1001/jamapsychiatry.2014.453.CrossRefPubMedGoogle Scholar
  17. 17.
    Brown GG, Lee JS, Strigo IA, Caligiuri MP, Meloy MJ, Lohr J. Voxel-based morphometry of patients with schizophrenia or bipolar I disorder: a matched control study. Psychiatry Res. 2011;194(2):149–56.  https://doi.org/10.1016/j.pscychresns.2011.05.005.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Hartberg CB, Sundet K, Rimol LM, Haukvik UK, Lange EH, Nesvag R, Melle I, Andreassen OA, Agartz I. Subcortical brain volumes relate to neurocognition in schizophrenia and bipolar disorder and healthy controls. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35(4):1122–30.  https://doi.org/10.1016/j.pnpbp.2011.03.014.CrossRefGoogle Scholar
  19. 19.
    Watson DR, Anderson JM, Bai F, Barrett SL, McGinnity TM, Mulholland CC, Rushe TM, Cooper SJ. A voxel based morphometry study investigating brain structural changes in first episode psychosis. Behav Brain Res. 2012;227(1):91–9.  https://doi.org/10.1016/j.bbr.2011.10.034.CrossRefPubMedGoogle Scholar
  20. 20.
    Haukvik UK, Westlye LT, Morch-Johnsen L, Jorgensen KN, Lange EH, Dale AM, Melle I, Andreassen OA, Agartz I. In vivo hippocampal subfield volumes in schizophrenia and bipolar disorder. Biol Psychiatry. 2015;77(6):581–8.  https://doi.org/10.1016/j.biopsych.2014.06.020.CrossRefPubMedGoogle Scholar
  21. 21.
    Knochel C, Stablein M, Storchak H, Reinke B, Jurcoane A, Prvulovic D, Linden DE, van de Ven V, Ghinea D, Wenzler S, Alves G, Matura S, Kroger A, Oertel-Knochel V. Multimodal assessments of the hippocampal formation in schizophrenia and bipolar disorder: evidences from neurobehavioral measures and functional and structural MRI. Neuroimage Clin. 2014;6:134–44.  https://doi.org/10.1016/j.nicl.2014.08.015.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Olabi B, Ellison-Wright I, McIntosh AM, Wood SJ, Bullmore E, Lawrie SM. Are there progressive brain changes in schizophrenia? A meta-analysis of structural magnetic resonance imaging studies. Biol Psychiatry. 2011;70(1):88–96.  https://doi.org/10.1016/j.biopsych.2011.01.032.CrossRefPubMedGoogle Scholar
  23. 23.
    Fusar-Poli P, Meyer-Lindenberg A. Striatal presynaptic dopamine in schizophrenia, part II: meta-analysis of [(18)F/(11)C]-DOPA PET studies. Schizophr Bull. 2013;39(1):33–42.  https://doi.org/10.1093/schbul/sbr180.CrossRefPubMedGoogle Scholar
  24. 24.
    Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC. Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry. 2009;66(8):811–22.  https://doi.org/10.1001/archgenpsychiatry.2009.91.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Smieskova R, Marmy J, Schmidt A, Bendfeldt K, Riecher-Rssler A, Walter M, Lang UE, Borgwardt S. Do subjects at clinical high risk for psychosis differ from those with a genetic high risk? A systematic review of structural and functional brain abnormalities. Curr Med Chem. 2013;20(3):467–81.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Taylor SF, Kang J, Brege IS, Tso IF, Hosanagar A, Johnson TD. Meta-analysis of functional neuroimaging studies of emotion perception and experience in schizophrenia. Biol Psychiatry. 2012;71(2):136–45.  https://doi.org/10.1016/j.biopsych.2011.09.007.CrossRefPubMedGoogle Scholar
  27. 27.
    Fusar-Poli P. Voxel-wise meta-analysis of fMRI studies in patients at clinical high risk for psychosis. J Psychiatry Neurosci. 2012;37(2):106–12.  https://doi.org/10.1503/jpn.110021.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Radua J, Borgwardt S, Crescini A, Mataix-Cols D, Meyer-Lindenberg A, McGuire PK, Fusar-Poli P. Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication. Neurosci Biobehav Rev. 2012;36(10):2325–33.  https://doi.org/10.1016/j.neubiorev.2012.07.012.CrossRefPubMedGoogle Scholar
  29. 29.
    Jardri R, Pouchet A, Pins D, Thomas P. Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. Am J Psychiatry. 2011;168(1):73–81.  https://doi.org/10.1176/appi.ajp.2010.09101522.CrossRefPubMedGoogle Scholar
  30. 30.
    Cooper D, Barker V, Radua J, Fusar-Poli P, Lawrie SM. Multimodal voxel-based meta-analysis of structural and functional magnetic resonance imaging studies in those at elevated genetic risk of developing schizophrenia. Psychiatry Res. 2014;221(1):69–77.  https://doi.org/10.1016/j.pscychresns.2013.07.008.CrossRefPubMedGoogle Scholar
  31. 31.
    Szeszko PR, Robinson DG, Ashtari M, Vogel J, Betensky J, Sevy S, Ardekani BA, Lencz T, Malhotra AK, McCormack J, Miller R, Lim KO, Gunduz-Bruce H, Kane JM, Bilder RM. Clinical and neuropsychological correlates of white matter abnormalities in recent onset schizophrenia. Neuropsychopharmacology. 2008;33(5):976–84.  https://doi.org/10.1038/sj.npp.1301480.CrossRefPubMedGoogle Scholar
  32. 32.
    Price G, Cercignani M, Parker GJ, Altmann DR, Barnes TR, Barker GJ, Joyce EM, Ron MA. White matter tracts in first-episode psychosis: a DTI tractography study of the uncinate fasciculus. NeuroImage. 2008;39(3):949–55.  https://doi.org/10.1016/j.neuroimage.2007.09.012.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Hovington CL, Bodnar M, Chakravarty MM, Joober R, Malla AK, Lepage M. Investigation of white matter abnormalities in first episode psychosis patients with persistent negative symptoms. Psychiatry Res. 2015;233(3):402–8.  https://doi.org/10.1016/j.pscychresns.2015.06.017.CrossRefPubMedGoogle Scholar
  34. 34.
    Ellison-Wright I, Bullmore E. Meta-analysis of diffusion tensor imaging studies in schizophrenia. Schizophr Res. 2009;108(1–3):3–10.  https://doi.org/10.1016/j.schres.2008.11.021.CrossRefGoogle Scholar
  35. 35.
    Zhou Y, Liu J, Driesen N, Womer F, Chen K, Wang Y, Jiang X, Zhou Q, Bai C, Wang D, Tang Y, Wang F. White matter integrity in genetic high-risk individuals and first-episode schizophrenia patients: similarities and disassociations. Biomed Res Int. 2017;2017:3107845.  https://doi.org/10.1155/2017/3107845.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Zhou Y, Shu N, Liu Y, Song M, Hao Y, Liu H, Yu C, Liu Z, Jiang T. Altered resting-state functional connectivity and anatomical connectivity of hippocampus in schizophrenia. Schizophr Res. 2008;100(1–3):120–32.  https://doi.org/10.1016/j.schres.2007.11.039.CrossRefPubMedGoogle Scholar
  37. 37.
    Price G, Cercignani M, Parker GJ, Altmann DR, Barnes TR, Barker GJ, Joyce EM, Ron MA. Abnormal brain connectivity in first-episode psychosis: a diffusion MRI tractography study of the corpus callosum. NeuroImage. 2007;35(2):458–66.  https://doi.org/10.1016/j.neuroimage.2006.12.019.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Kraguljac NV, Reid M, White D, Jones R, den Hollander J, Lowman D, Lahti AC. Neurometabolites in schizophrenia and bipolar disorder - a systematic review and meta-analysis. Psychiatry Res. 2012;203(2–3):111–25.  https://doi.org/10.1016/j.pscychresns.2012.02.003.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Galderisi S, Farden A, Kaiser S. Dissecting negative symptoms of schizophrenia: history, assessment, pathophysiological mechanisms and treatment. Schizophr Res. 2017;186:1–2.  https://doi.org/10.1016/j.schres.2016.04.046.CrossRefPubMedGoogle Scholar
  40. 40.
    Carpenter WT Jr, Heinrichs DW, Wagman AM. Deficit and nondeficit forms of schizophrenia: the concept. Am J Psychiatry. 1988;145(5):578–83.  https://doi.org/10.1176/ajp.145.5.578.CrossRefPubMedGoogle Scholar
  41. 41.
    Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry. 1998;155(6):751–60.  https://doi.org/10.1176/ajp.155.6.751.CrossRefPubMedGoogle Scholar
  42. 42.
    Galderisi S, Maj M, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Dell’Osso L, Daneluzzo E, Pini S. Historical, psychopathological, neurological, and neuropsychological aspects of deficit schizophrenia: a multicenter study. Am J Psychiatry. 2002;159(6):983–90.  https://doi.org/10.1176/appi.ajp.159.6.983.CrossRefPubMedGoogle Scholar
  43. 43.
    Kirkpatrick B, Buchanan RW, Ross DE, Carpenter WT Jr. A separate disease within the syndrome of schizophrenia. Arch Gen Psychiatry. 2001;58(2):165–71.CrossRefGoogle Scholar
  44. 44.
    Galderisi S, Bucci P, Mucci A, Kirkpatrick B, Pini S, Rossi A, Vita A, Maj M. Categorical and dimensional approaches to negative symptoms of schizophrenia: focus on long-term stability and functional outcome. Schizophr Res. 2013;147(1):157–62.  https://doi.org/10.1016/j.schres.2013.03.020.CrossRefPubMedGoogle Scholar
  45. 45.
    Cohen AS, Saperstein AM, Gold JM, Kirkpatrick B, Carpenter WT Jr, Buchanan RW. Neuropsychology of the deficit syndrome: new data and meta-analysis of findings to date. Schizophr Bull. 2007;33(5):1201–12.  https://doi.org/10.1093/schbul/sbl066.CrossRefPubMedGoogle Scholar
  46. 46.
    Turetsky B, Cowell PE, Gur RC, Grossman RI, Shtasel DL, Gur RE. Frontal and temporal lobe brain volumes in schizophrenia. Relationship to symptoms and clinical subtype. Arch Gen Psychiatry. 1995;52(12):1061–70.CrossRefGoogle Scholar
  47. 47.
    Galderisi S, Quarantelli M, Volpe U, Mucci A, Cassano GB, Invernizzi G, Rossi A, Vita A, Pini S, Cassano P, Daneluzzo E, De Peri L, Stratta P, Brunetti A, Maj M. Patterns of structural MRI abnormalities in deficit and nondeficit schizophrenia. Schizophr Bull. 2008;34(2):393–401.  https://doi.org/10.1093/schbul/sbm097.CrossRefPubMedGoogle Scholar
  48. 48.
    Cascella NG, Fieldstone SC, Rao VA, Pearlson GD, Sawa A, Schretlen DJ. Gray-matter abnormalities in deficit schizophrenia. Schizophr Res. 2010;120(1–3):63–70.  https://doi.org/10.1016/j.schres.2010.03.039.CrossRefPubMedGoogle Scholar
  49. 49.
    Fischer BA, Keller WR, Arango C, Pearlson GD, McMahon RP, Meyer WA, Francis A, Kirkpatrick B, Carpenter WT, Buchanan RW. Cortical structural abnormalities in deficit versus nondeficit schizophrenia. Schizophr Res. 2012;136(1–3):51–4.  https://doi.org/10.1016/j.schres.2012.01.030.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW. White matter alterations in deficit schizophrenia. Neuropsychopharmacology. 2009;34(6):1514–22.  https://doi.org/10.1038/npp.2008.207.CrossRefPubMedGoogle Scholar
  51. 51.
    Kitis O, Ozalay O, Zengin EB, Haznedaroglu D, Eker MC, Yalvac D, Oguz K, Coburn K, Gonul AS. Reduced left uncinate fasciculus fractional anisotropy in deficit schizophrenia but not in non-deficit schizophrenia. Psychiatry Clin Neurosci. 2012;66(1):34–43.  https://doi.org/10.1111/j.1440-1819.2011.02293.x.CrossRefPubMedGoogle Scholar
  52. 52.
    Voineskos AN, Foussias G, Lerch J, Felsky D, Remington G, Rajji TK, Lobaugh N, Pollock BG, Mulsant BH. Neuroimaging evidence for the deficit subtype of schizophrenia. JAMA Psychiatry. 2013;70(5):472–80.  https://doi.org/10.1001/jamapsychiatry.2013.786.CrossRefPubMedGoogle Scholar
  53. 53.
    Galderisi S, Merlotti E, Mucci A. Neurobiological background of negative symptoms. Eur Arch Psychiatry Clin Neurosci. 2015;265(7):543–58.  https://doi.org/10.1007/s00406-015-0590-4.CrossRefPubMedGoogle Scholar
  54. 54.
    Mucci A, Merlotti E, Ucok A, Aleman A, Galderisi S. Primary and persistent negative symptoms: concepts, assessments and neurobiological bases. Schizophr Res. 2017;186:19–28.  https://doi.org/10.1016/j.schres.2016.05.014.CrossRefPubMedGoogle Scholar
  55. 55.
    Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. Lancet Psychiatry. 2018;  https://doi.org/10.1016/S2215-0366(18)30050-6.CrossRefGoogle Scholar
  56. 56.
    Fusar-Poli P, Cappucciati M, Rutigliano G, Schultze-Lutter F, Bonoldi I, Borgwardt S, Riecher-Rossler A, Addington J, Perkins D, Woods SW, McGlashan TH, Lee J, Klosterkotter J, Yung AR, McGuire P. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. World Psychiatry. 2015;14(3):322–32.  https://doi.org/10.1002/wps.20250.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Kempton MJ, McGuire P. How can neuroimaging facilitate the diagnosis and stratification of patients with psychosis? Eur Neuropsychopharmacol. 2015;25(5):725–32.  https://doi.org/10.1016/j.euroneuro.2014.07.006.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Emsley R, Rabinowitz J, Medori R, Early Psychosis Global Working Group. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res. 2007;89(1–3):129–39.  https://doi.org/10.1016/j.schres.2006.09.013.CrossRefPubMedGoogle Scholar
  59. 59.
    Lambert M, Naber D, Schacht A, Wagner T, Hundemer HP, Karow A, Huber CG, Suarez D, Haro JM, Novick D, Dittmann RW, Schimmelmann BG. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand. 2008;118(3):220–9.  https://doi.org/10.1111/j.1600-0447.2008.01213.x.CrossRefPubMedGoogle Scholar
  60. 60.
    Borgwardt S, Schmidt A. Is neuroimaging clinically useful in subjects at high risk for psychosis? World Psychiatry. 2016;15(2):178–9.  https://doi.org/10.1002/wps.20333.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, Yung AR, Bullmore ET, Brewer W, Soulsby B, Desmond P, McGuire PK. Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and longitudinal MRI comparison. Lancet (London, England). 2003;361(9354):281–8.  https://doi.org/10.1016/s0140-6736(03)12323-9.CrossRefGoogle Scholar
  62. 62.
    Walterfang M, Yung A, Wood AG, Reutens DC, Phillips L, Wood SJ, Chen J, Velakoulis D, McGorry PD, Pantelis C. Corpus callosum shape alterations in individuals prior to the onset of psychosis. Schizophr Res. 2008;103(1–3):1–10.  https://doi.org/10.1016/j.schres.2008.04.042.CrossRefPubMedGoogle Scholar
  63. 63.
    Meijer JH, Schmitz N, Nieman DH, Becker HE, van Amelsvoort TA, Dingemans PM, Linszen DH, de Haan L. Semantic fluency deficits and reduced grey matter before transition to psychosis: a voxelwise correlational analysis. Psychiatry Res. 2011;194(1):1–6.  https://doi.org/10.1016/j.pscychresns.2011.01.004.CrossRefPubMedGoogle Scholar
  64. 64.
    Borgwardt SJ, McGuire PK, Aston J, Berger G, Dazzan P, Gschwandtner U, Pfluger M, D’Souza M, Radue EW, Riecher-Rossler A. Structural brain abnormalities in individuals with an at-risk mental state who later develop psychosis. Br J Psychiatry Suppl. 2007;51:s69–75.  https://doi.org/10.1192/bjp.191.51.s69.CrossRefPubMedGoogle Scholar
  65. 65.
    Borgwardt SJ, McGuire PK, Aston J, Gschwandtner U, Pfluger MO, Stieglitz RD, Radue EW, Riecher-Rossler A. Reductions in frontal, temporal and parietal volume associated with the onset of psychosis. Schizophr Res. 2008;106(2–3):108–14.  https://doi.org/10.1016/j.schres.2008.08.007.CrossRefPubMedGoogle Scholar
  66. 66.
    Das T, Borgwardt S, Hauke DJ, Harrisberger F, Lang UE, Riecher-Rossler A, Palaniyappan L, Schmidt A. Disorganized gyrification network properties during the transition to psychosis. JAMA Psychiatry. 2018;  https://doi.org/10.1001/jamapsychiatry.2018.0391.CrossRefGoogle Scholar
  67. 67.
    Bloemen OJ, de Koning MB, Schmitz N, Nieman DH, Becker HE, de Haan L, Dingemans P, Linszen DH, van Amelsvoort TA. White-matter markers for psychosis in a prospective ultra-high-risk cohort. Psychol Med. 2010;40(8):1297–304.  https://doi.org/10.1017/s0033291709991711.CrossRefPubMedGoogle Scholar
  68. 68.
    de la Fuente-Sandoval C, Leon-Ortiz P, Azcarraga M, Favila R, Stephano S, Graff-Guerrero A. Striatal glutamate and the conversion to psychosis: a prospective 1H-MRS imaging study. Int J Neuropsychopharmacol. 2013;16(2):471–5.  https://doi.org/10.1017/s1461145712000314.CrossRefPubMedGoogle Scholar
  69. 69.
    Cannon TD, Chung Y, He G, Sun D, Jacobson A, van Erp TG, McEwen S, Addington J, Bearden CE, Cadenhead K, Cornblatt B, Mathalon DH, McGlashan T, Perkins D, Jeffries C, Seidman LJ, Tsuang M, Walker E, Woods SW, Heinssen R, North American Prodrome Longitudinal Study Consortium. Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk. Biol Psychiatry. 2015;77(2):147–57.  https://doi.org/10.1016/j.biopsych.2014.05.023.CrossRefPubMedGoogle Scholar
  70. 70.
    Ziermans TB, Schothorst PF, Schnack HG, Koolschijn PC, Kahn RS, van Engeland H, Durston S. Progressive structural brain changes during development of psychosis. Schizophr Bull. 2012;38(3):519–30.  https://doi.org/10.1093/schbul/sbq113.CrossRefPubMedGoogle Scholar
  71. 71.
    Peters BD, Dingemans PM, Dekker N, Blaas J, Akkerman E, van Amelsvoort TA, Majoie CB, den Heeten GJ, Linszen DH, de Haan L. White matter connectivity and psychosis in ultra-high-risk subjects: a diffusion tensor fiber tracking study. Psychiatry Res. 2010;181(1):44–50.  https://doi.org/10.1016/j.pscychresns.2009.10.008.CrossRefPubMedGoogle Scholar
  72. 72.
    Howes OD, Bose SK, Turkheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P. Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry. 2011;168(12):1311–7.  https://doi.org/10.1176/appi.ajp.2011.11010160.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr Q. 2000;71(4):373–84.CrossRefGoogle Scholar
  74. 74.
    Li J, Meltzer HY. A genetic locus in 7p12.2 associated with treatment resistant schizophrenia. Schizophr Res. 2014;159(2–3):333–9.  https://doi.org/10.1016/j.schres.2014.08.018.CrossRefPubMedGoogle Scholar
  75. 75.
    Teo C, Zai C, Borlido C, Tomasetti C, Strauss J, Shinkai T, Le Foll B, Wong A, Kennedy JL, De Luca V. Analysis of treatment-resistant schizophrenia and 384 markers from candidate genes. Pharmacogenet Genomics. 2012;22(11):807–11.  https://doi.org/10.1097/FPC.0b013e3283586c04.CrossRefPubMedGoogle Scholar
  76. 76.
    Howes OD, Vergunst F, Gee S, McGuire P, Kapur S, Taylor D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry. 2012;201(6):481–5.  https://doi.org/10.1192/bjp.bp.111.105833.CrossRefPubMedGoogle Scholar
  77. 77.
    Reis Marques T, Taylor H, Chaddock C, Dell’Acqua F, Handley R, Reinders AATS, Mondelli V, Bonaccorso S, DiForti M, Simmons A, Murray RM, Pariante CM, Kapur S, Dazzan P. White matter integrity as a predictor of response to treatment in first episode psychosis. Brain. 2014;137:172–82. (0006-8950 (Print)).CrossRefGoogle Scholar
  78. 78.
    Palaniyappan L, Marques TR, Taylor H, Handley R, Mondelli V, Bonaccorso S, Giordano A, McQueen G, DiForti M, Simmons A, David AS, Pariante CM, Murray RM, Dazzan P. Cortical folding defects as markers of poor treatment response in first-episode psychosis. JAMA Psychiatry. 2013;70(10):1031–40.  https://doi.org/10.1001/jamapsychiatry.2013.203.CrossRefPubMedGoogle Scholar
  79. 79.
    Howes OD, Kapur S. A neurobiological hypothesis for the classification of schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). Br J Psychiatry. 2014;205(1):1–3.  https://doi.org/10.1192/bjp.bp.113.138578.CrossRefPubMedGoogle Scholar
  80. 80.
    McGuire P, Howes OD, Stone J, Fusar-Poli P. Functional neuroimaging in schizophrenia: diagnosis and drug discovery. Trends Pharmacol Sci. 2008;29(2):91–8.  https://doi.org/10.1016/j.tips.2007.11.005.CrossRefPubMedGoogle Scholar
  81. 81.
    Abi-Dargham A, Rodenhiser J, Printz D, Zea-Ponce Y, Gil R, Kegeles LS, Weiss R, Cooper TB, Mann JJ, Van Heertum RL, Gorman JM, Laruelle M. Increased baseline occupancy of D2 receptors by dopamine in schizophrenia. Proc Natl Acad Sci U S A. 2000;97(14):8104–9.CrossRefGoogle Scholar
  82. 82.
    Demjaha A, Murray RM, McGuire PK, Kapur S, Howes OD. Dopamine synthesis capacity in patients with treatment-resistant schizophrenia. Am J Psychiatry. 2012;169(11):1203–10.  https://doi.org/10.1176/appi.ajp.2012.12010144.CrossRefPubMedGoogle Scholar
  83. 83.
    Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P, Bramon-Bosch E, Valmaggia L, Johns L, Broome M, McGuire PK, Grasby PM. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry. 2009;66(1):13–20.  https://doi.org/10.1001/archgenpsychiatry.2008.514.CrossRefPubMedGoogle Scholar
  84. 84.
    Egerton A, Chaddock CA, Winton-Brown TT, Bloomfield MA, Bhattacharyya S, Allen P, McGuire PK, Howes OD. Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry. 2013;74(2):106–12.  https://doi.org/10.1016/j.biopsych.2012.11.017.CrossRefPubMedGoogle Scholar
  85. 85.
    Howes O, McCutcheon R, Stone J. Glutamate and dopamine in schizophrenia: an update for the 21st century. J Psychopharmacol. 2015;29(2):97–115.  https://doi.org/10.1177/0269881114563634.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. Schizophr Res. 2014;152(2–3):325–32.  https://doi.org/10.1016/j.schres.2013.12.013.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, Abi-Dargham A, Girgis RR. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19(1):20–9.  https://doi.org/10.1038/mp.2013.136.CrossRefPubMedGoogle Scholar
  88. 88.
    Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, Stone JM. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology. 2012;37(11):2515–21.  https://doi.org/10.1038/npp.2012.113.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Demjaha A, Egerton A, Murray RM, Kapur S, Howes OD, Stone JM, McGuire PK. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry. 2014;75(5):e11–3.  https://doi.org/10.1016/j.biopsych.2013.06.011.CrossRefGoogle Scholar
  90. 90.
    Mouchlianitis E, Bloomfield MA, Law V, Beck K, Selvaraj S, Rasquinha N, Waldman A, Turkheimer FE, Egerton A, Stone J, Howes OD. Treatment-resistant schizophrenia patients show elevated anterior cingulate cortex glutamate compared to treatment-responsive. Schizophr Bull. 2016;42(3):744–52.  https://doi.org/10.1093/schbul/sbv151.CrossRefPubMedGoogle Scholar
  91. 91.
    Egerton A, Bhachu A, Merritt K, McQueen G, Szulc A, McGuire P. Effects of antipsychotic administration on brain glutamate in schizophrenia: a systematic review of longitudinal (1)H-MRS studies. Front Psychiatry. 2017;8:66.  https://doi.org/10.3389/fpsyt.2017.00066.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Mamdani F, Martin MV, Lencz T, Rollins B, Robinson DG, Moon EA, Malhotra AK, Vawter MP. Coding and noncoding gene expression biomarkers in mood disorders and schizophrenia. Dis Markers. 2013;35(1):11–21.  https://doi.org/10.1155/2013/748095.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Insel TR, Cuthbert BN. Medicine. Brain disorders? Precisely. Science. 2015;348(6234):499–500.  https://doi.org/10.1126/science.aab2358.CrossRefPubMedGoogle Scholar
  94. 94.
    O’Halloran R, Kopell BH, Sprooten E, Goodman WK, Frangou S. Multimodal neuroimaging-informed clinical applications in neuropsychiatric disorders. Front Psychiatry. 2016;7:63.  https://doi.org/10.3389/fpsyt.2016.00063.CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Calhoun VD, Sui J. Multimodal fusion of brain imaging data: a key to finding the missing link(s) in complex mental illness. Biol Psychiatry Cogn Neurosci Neuroimaging. 2016;1(3):230–44.  https://doi.org/10.1016/j.bpsc.2015.12.005.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Moser DA, Doucet GE, Lee WH, Rasgon A, Krinsky H, Leibu E, Ing A, Schumann G, Rasgon N, Frangou S. Multivariate associations among behavioral, clinical, and multimodal imaging phenotypes in patients with psychosis. JAMA Psychiatry. 2018;75(4):386–95.  https://doi.org/10.1001/jamapsychiatry.2017.4741.CrossRefPubMedGoogle Scholar
  97. 97.
    Thompson PM, Stein JL, Medland SE, Hibar DP, Vasquez AA, Renteria ME, Toro R, Jahanshad N, Schumann G, Franke B, Wright MJ, Martin NG, Agartz I, Alda M, Alhusaini S, Almasy L, Almeida J, Alpert K, Andreasen NC, Andreassen OA, Apostolova LG, Appel K, Armstrong NJ, Aribisala B, Bastin ME, Bauer M, Bearden CE, Bergmann O, Binder EB, Blangero J, Bockholt HJ, Boen E, Bois C, Boomsma DI, Booth T, Bowman IJ, Bralten J, Brouwer RM, Brunner HG, Brohawn DG, Buckner RL, Buitelaar J, Bulayeva K, Bustillo JR, Calhoun VD, Cannon DM, Cantor RM, Carless MA, Caseras X, Cavalleri GL, Chakravarty MM, Chang KD, Ching CR, Christoforou A, Cichon S, Clark VP, Conrod P, Coppola G, Crespo-Facorro B, Curran JE, Czisch M, Deary IJ, de Geus EJ, den Braber A, Delvecchio G, Depondt C, de Haan L, de Zubicaray GI, Dima D, Dimitrova R, Djurovic S, Dong H, Donohoe G, Duggirala R, Dyer TD, Ehrlich S, Ekman CJ, Elvsashagen T, Emsell L, Erk S, Espeseth T, Fagerness J, Fears S, Fedko I, Fernandez G, Fisher SE, Foroud T, Fox PT, Francks C, Frangou S, Frey EM, Frodl T, Frouin V, Garavan H, Giddaluru S, Glahn DC, Godlewska B, Goldstein RZ, Gollub RL, Grabe HJ, Grimm O, Gruber O, Guadalupe T, Gur RE, Gur RC, Goring HH, Hagenaars S, Hajek T, Hall GB, Hall J, Hardy J, Hartman CA, Hass J, Hatton SN, Haukvik UK, Hegenscheid K, Heinz A, Hickie IB, Ho BC, Hoehn D, Hoekstra PJ, Hollinshead M, Holmes AJ, Homuth G, Hoogman M, Hong LE, Hosten N, Hottenga JJ, Hulshoff Pol HE, Hwang KS, Jack CR Jr, Jenkinson M, Johnston C, Jonsson EG, Kahn RS, Kasperaviciute D, Kelly S, Kim S, Kochunov P, Koenders L, Kramer B, Kwok JB, Lagopoulos J, Laje G, Landen M, Landman BA, Lauriello J, Lawrie SM, Lee PH, Le Hellard S, Lemaitre H, Leonardo CD, Li CS, Liberg B, Liewald DC, Liu X, Lopez LM, Loth E, Lourdusamy A, Luciano M, Macciardi F, Machielsen MW, Macqueen GM, Malt UF, Mandl R, Manoach DS, Martinot JL, Matarin M, Mather KA, Mattheisen M, Mattingsdal M, Meyer-Lindenberg A, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Meisenzahl E, Melle I, Milaneschi Y, Mohnke S, Montgomery GW, Morris DW, Moses EK, Mueller BA, Munoz Maniega S, Muhleisen TW, Muller-Myhsok B, Mwangi B, Nauck M, Nho K, Nichols TE, Nilsson LG, Nugent AC, Nyberg L, Olvera RL, Oosterlaan J, Ophoff RA, Pandolfo M, Papalampropoulou-Tsiridou M, Papmeyer M, Paus T, Pausova Z, Pearlson GD, Penninx BW, Peterson CP, Pfennig A, Phillips M, Pike GB, Poline JB, Potkin SG, Putz B, Ramasamy A, Rasmussen J, Rietschel M, Rijpkema M, Risacher SL, Roffman JL, Roiz-Santianez R, Romanczuk-Seiferth N, Rose EJ, Royle NA, Rujescu D, Ryten M, Sachdev PS, Salami A, Satterthwaite TD, Savitz J, Saykin AJ, Scanlon C, Schmaal L, Schnack HG, Schork AJ, Schulz SC, Schur R, Seidman L, Shen L, Shoemaker JM, Simmons A, Sisodiya SM, Smith C, Smoller JW, Soares JC, Sponheim SR, Sprooten E, Starr JM, Steen VM, Strakowski S, Strike L, Sussmann J, Samann PG, Teumer A, Toga AW, Tordesillas-Gutierrez D, Trabzuni D, Trost S, Turner J, Van den Heuvel M, van der Wee NJ, van Eijk K, van Erp TG, van Haren NE, van’t Ent D, van Tol MJ, Valdes Hernandez MC, Veltman DJ, Versace A, Volzke H, Walker R, Walter H, Wang L, Wardlaw JM, Weale ME, Weiner MW, Wen W, Westlye LT, Whalley HC, Whelan CD, White T, Winkler AM, Wittfeld K, Woldehawariat G, Wolf C, Zilles D, Zwiers MP, Thalamuthu A, Schofield PR, Freimer NB, Lawrence NS, Drevets W, Alzheimer’s Disease Neuroimaging Initiative, EPIGEN Consortium, IMAGEN Consortium, Saguenay Youth Study (SYS) Group. The ENIGMA Consortium: large-scale collaborative analyses of neuroimaging and genetic data. Brain Imaging Behav. 2014;8(2):153–82.  https://doi.org/10.1007/s11682-013-9269-5.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Hibar DP, Adams HHH, Jahanshad N, Chauhan G, Stein JL, Hofer E, Renteria ME, Bis JC, Arias-Vasquez A, Ikram MK, Desrivieres S, Vernooij MW, Abramovic L, Alhusaini S, Amin N, Andersson M, Arfanakis K, Aribisala BS, Armstrong NJ, Athanasiu L, Axelsson T, Beecham AH, Beiser A, Bernard M, Blanton SH, Bohlken MM, Boks MP, Bralten J, Brickman AM, Carmichael O, Chakravarty MM, Chen Q, Ching CRK, Chouraki V, Cuellar-Partida G, Crivello F, Den Braber A, Doan NT, Ehrlich S, Giddaluru S, Goldman AL, Gottesman RF, Grimm O, Griswold ME, Guadalupe T, Gutman BA, Hass J, Haukvik UK, Hoehn D, Holmes AJ, Hoogman M, Janowitz D, Jia T, Jorgensen KN, Karbalai N, Kasperaviciute D, Kim S, Klein M, Kraemer B, Lee PH, Liewald DCM, Lopez LM, Luciano M, Macare C, Marquand AF, Matarin M, Mather KA, Mattheisen M, McKay DR, Milaneschi Y, Munoz Maniega S, Nho K, Nugent AC, Nyquist P, Loohuis LMO, Oosterlaan J, Papmeyer M, Pirpamer L, Putz B, Ramasamy A, Richards JS, Risacher SL, Roiz-Santianez R, Rommelse N, Ropele S, Rose EJ, Royle NA, Rundek T, Samann PG, Saremi A, Satizabal CL, Schmaal L, Schork AJ, Shen L, Shin J, Shumskaya E, Smith AV, Sprooten E, Strike LT, Teumer A, Tordesillas-Gutierrez D, Toro R, Trabzuni D, Trompet S, Vaidya D, Van der Grond J, Van der Lee SJ, Van der Meer D, Van Donkelaar MMJ, Van Eijk KR, Van Erp TGM, Van Rooij D, Walton E, Westlye LT, Whelan CD, Windham BG, Winkler AM, Wittfeld K, Woldehawariat G, Wolf C, Wolfers T, Yanek LR, Yang J, Zijdenbos A, Zwiers MP, Agartz I, Almasy L, Ames D, Amouyel P, Andreassen OA, Arepalli S, Assareh AA, Barral S, Bastin ME, Becker DM, Becker JT, Bennett DA, Blangero J, van Bokhoven H, Boomsma DI, Brodaty H, Brouwer RM, Brunner HG, Buckner RL, Buitelaar JK, Bulayeva KB, Cahn W, Calhoun VD, Cannon DM, Cavalleri GL, Cheng CY, Cichon S, Cookson MR, Corvin A, Crespo-Facorro B, Curran JE, Czisch M, Dale AM, Davies GE, De Craen AJM, De Geus EJC, De Jager PL, De Zubicaray GI, Deary IJ, Debette S, DeCarli C, Delanty N, Depondt C, DeStefano A, Dillman A, Djurovic S, Donohoe G, Drevets WC, Duggirala R, Dyer TD, Enzinger C, Erk S, Espeseth T, Fedko IO, Fernandez G, Ferrucci L, Fisher SE, Fleischman DA, Ford I, Fornage M, Foroud TM, Fox PT, Francks C, Fukunaga M, Gibbs JR, Glahn DC, Gollub RL, Goring HHH, Green RC, Gruber O, Gudnason V, Guelfi S, Haberg AK, Hansell NK, Hardy J, Hartman CA, Hashimoto R, Hegenscheid K, Heinz A, Le Hellard S, Hernandez DG, Heslenfeld DJ, Ho BC, Hoekstra PJ, Hoffmann W, Hofman A, Holsboer F, Homuth G, Hosten N, Hottenga JJ, Huentelman M, Hulshoff Pol HE, Ikeda M, Jack CR Jr, Jenkinson M, Johnson R, Jonsson EG, Jukema JW, Kahn RS, Kanai R, Kloszewska I, Knopman DS, Kochunov P, Kwok JB, Lawrie SM, Lemaitre H, Liu X, Longo DL, Lopez OL, Lovestone S, Martinez O, Martinot JL, Mattay VS, McDonald C, McIntosh AM, McMahon FJ, McMahon KL, Mecocci P, Melle I, Meyer-Lindenberg A, Mohnke S, Montgomery GW, Morris DW, Mosley TH, Muhleisen TW, Muller-Myhsok B, Nalls MA, Nauck M, Nichols TE, Niessen WJ, Nothen MM, Nyberg L, Ohi K, Olvera RL, Ophoff RA, Pandolfo M, Paus T, Pausova Z, Penninx B, Pike GB, Potkin SG, Psaty BM, Reppermund S, Rietschel M, Roffman JL, Romanczuk-Seiferth N, Rotter JI, Ryten M, Sacco RL, Sachdev PS, Saykin AJ, Schmidt R, Schmidt H, Schofield PR, Sigursson S, Simmons A, Singleton A, Sisodiya SM, Smith C, Smoller JW, Soininen H, Steen VM, Stott DJ, Sussmann JE, Thalamuthu A, Toga AW, Traynor BJ, Troncoso J, Tsolaki M, Tzourio C, Uitterlinden AG, Hernandez MCV, Van der Brug M, van der Lugt A, van der Wee NJA, Van Haren NEM, van’t Ent D, Van Tol MJ, Vardarajan BN, Vellas B, Veltman DJ, Volzke H, Walter H, Wardlaw JM, Wassink TH, Weale ME, Weinberger DR, Weiner MW, Wen W, Westman E, White T, Wong TY, Wright CB, Zielke RH, Zonderman AB, Martin NG, Van Duijn CM, Wright MJ, Longstreth WT, Schumann G, Grabe HJ, Franke B, Launer LJ, Medland SE, Seshadri S, Thompson PM, Ikram MA. Novel genetic loci associated with hippocampal volume. Nat Commun. 2017;8:13624.  https://doi.org/10.1038/ncomms13624.CrossRefPubMedPubMedCentralGoogle Scholar
  99. 99.
    Stein JL, Medland SE, Vasquez AA, Hibar DP, Senstad RE, Winkler AM, Toro R, Appel K, Bartecek R, Bergmann O, Bernard M, Brown AA, Cannon DM, Chakravarty MM, Christoforou A, Domin M, Grimm O, Hollinshead M, Holmes AJ, Homuth G, Hottenga JJ, Langan C, Lopez LM, Hansell NK, Hwang KS, Kim S, Laje G, Lee PH, Liu X, Loth E, Lourdusamy A, Mattingsdal M, Mohnke S, Maniega SM, Nho K, Nugent AC, O’Brien C, Papmeyer M, Putz B, Ramasamy A, Rasmussen J, Rijpkema M, Risacher SL, Roddey JC, Rose EJ, Ryten M, Shen L, Sprooten E, Strengman E, Teumer A, Trabzuni D, Turner J, van Eijk K, van Erp TG, van Tol MJ, Wittfeld K, Wolf C, Woudstra S, Aleman A, Alhusaini S, Almasy L, Binder EB, Brohawn DG, Cantor RM, Carless MA, Corvin A, Czisch M, Curran JE, Davies G, de Almeida MA, Delanty N, Depondt C, Duggirala R, Dyer TD, Erk S, Fagerness J, Fox PT, Freimer NB, Gill M, Goring HH, Hagler DJ, Hoehn D, Holsboer F, Hoogman M, Hosten N, Jahanshad N, Johnson MP, Kasperaviciute D, Kent JW Jr, Kochunov P, Lancaster JL, Lawrie SM, Liewald DC, Mandl R, Matarin M, Mattheisen M, Meisenzahl E, Melle I, Moses EK, Muhleisen TW, Nauck M, Nothen MM, Olvera RL, Pandolfo M, Pike GB, Puls R, Reinvang I, Renteria ME, Rietschel M, Roffman JL, Royle NA, Rujescu D, Savitz J, Schnack HG, Schnell K, Seiferth N, Smith C, Steen VM, Valdes Hernandez MC, Van den Heuvel M, van der Wee NJ, Van Haren NE, Veltman JA, Volzke H, Walker R, Westlye LT, Whelan CD, Agartz I, Boomsma DI, Cavalleri GL, Dale AM, Djurovic S, Drevets WC, Hagoort P, Hall J, Heinz A, Jack CR Jr, Foroud TM, Le Hellard S, Macciardi F, Montgomery GW, Poline JB, Porteous DJ, Sisodiya SM, Starr JM, Sussmann J, Toga AW, Veltman DJ, Walter H, Weiner MW, Alzheimer’s Disease Neuroimaging I, Consortium E, Consortium I, Saguenay Youth Study G, Bis JC, Ikram MA, Smith AV, Gudnason V, Tzourio C, Vernooij MW, Launer LJ, DeCarli C, Seshadri S, Cohorts for Heart Aging Research in Genomic Epidemiology Consortium, Andreassen OA, Apostolova LG, Bastin ME, Blangero J, Brunner HG, Buckner RL, Cichon S, Coppola G, de Zubicaray GI, Deary IJ, Donohoe G, de Geus EJ, Espeseth T, Fernandez G, Glahn DC, Grabe HJ, Hardy J, Hulshoff Pol HE, Jenkinson M, Kahn RS, McDonald C, AM MI, FJ MM, KL MM, Meyer-Lindenberg A, Morris DW, Muller-Myhsok B, Nichols TE, Ophoff RA, Paus T, Pausova Z, Penninx BW, Potkin SG, Samann PG, Saykin AJ, Schumann G, Smoller JW, Wardlaw JM, Weale ME, Martin NG, Franke B, Wright MJ, Thompson PM, Enhancing Neuro Imaging Genetics Through Meta-Analysis Consortium. Identification of common variants associated with human hippocampal and intracranial volumes. Nat Genet. 2012;44(5):552–61.  https://doi.org/10.1038/ng.2250.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Bearden CE, Thompson PM. Emerging Global Initiatives in Neurogenetics: The Enhancing Neuroimaging Genetics through Meta-analysis (ENIGMA) Consortium. Neuron. 2017;94(2):232–6.  https://doi.org/10.1016/j.neuron.2017.03.033.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Dazzan P, Arango C, Fleischacker W, Galderisi S, Glenthoj B, Leucht S, Meyer-Lindenberg A, Kahn R, Rujescu D, Sommer I, Winter I, McGuire P. Magnetic resonance imaging and the prediction of outcome in first-episode schizophrenia: a review of current evidence and directions for future research. Schizophr Bull. 2015;41(3):574–83.  https://doi.org/10.1093/schbul/sbv024.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry. 2008;65(1):28–37.  https://doi.org/10.1001/archgenpsychiatry.2007.3.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Anticevic A, Haut K, Murray JD, Repovs G, Yang GJ, Diehl C, McEwen SC, Bearden CE, Addington J, Goodyear B, Cadenhead KS, Mirzakhanian H, Cornblatt BA, Olvet D, Mathalon DH, McGlashan TH, Perkins DO, Belger A, Seidman LJ, Tsuang MT, van Erp TG, Walker EF, Hamann S, Woods SW, Qiu M, Cannon TD. Association of thalamic dysconnectivity and conversion to psychosis in youth and young adults at elevated clinical risk. JAMA Psychiatry. 2015;72(9):882–91.  https://doi.org/10.1001/jamapsychiatry.2015.0566.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Chung Y, Cannon TD. Brain imaging during the transition from psychosis prodrome to schizophrenia. J Nerv Ment Dis. 2015;203(5):336–41.  https://doi.org/10.1097/NMD.0000000000000286.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Zarogianni E, Moorhead TW, Lawrie SM. Towards the identification of imaging biomarkers in schizophrenia, using multivariate pattern classification at a single-subject level. Neuroimage Clin. 2013;3:279–89.  https://doi.org/10.1016/j.nicl.2013.09.003.CrossRefPubMedPubMedCentralGoogle Scholar
  106. 106.
    Linden DE. The challenges and promise of neuroimaging in psychiatry. Neuron. 2012;73(1):8–22.  https://doi.org/10.1016/j.neuron.2011.12.014.CrossRefPubMedGoogle Scholar
  107. 107.
    Vieira S, Pinaya WH, Mechelli A. Using deep learning to investigate the neuroimaging correlates of psychiatric and neurological disorders: methods and applications. Neurosci Biobehav Rev. 2017;74(Pt A):58–75.  https://doi.org/10.1016/j.neubiorev.2017.01.002.CrossRefPubMedGoogle Scholar
  108. 108.
    Koutsouleris N, Meisenzahl EM, Davatzikos C, Bottlender R, Frodl T, Scheuerecker J, Schmitt G, Zetzsche T, Decker P, Reiser M, Moller HJ, Gaser C. Use of neuroanatomical pattern classification to identify subjects in at-risk mental states of psychosis and predict disease transition. Arch Gen Psychiatry. 2009;66(7):700–12.  https://doi.org/10.1001/archgenpsychiatry.2009.62.CrossRefPubMedPubMedCentralGoogle Scholar
  109. 109.
    Fu CH, Mourao-Miranda J, Costafreda SG, Khanna A, Marquand AF, Williams SC, Brammer MJ. Pattern classification of sad facial processing: toward the development of neurobiological markers in depression. Biol Psychiatry. 2008;63(7):656–62.  https://doi.org/10.1016/j.biopsych.2007.08.020.CrossRefPubMedGoogle Scholar
  110. 110.
    Orru G, Pettersson-Yeo W, Marquand AF, Sartori G, Mechelli A. Using Support Vector Machine to identify imaging biomarkers of neurological and psychiatric disease: a critical review. Neurosci Biobehav Rev. 2012;36(4):1140–52.  https://doi.org/10.1016/j.neubiorev.2012.01.004.CrossRefPubMedGoogle Scholar
  111. 111.
    Shen H, Wang L, Liu Y, Hu D. Discriminative analysis of resting-state functional connectivity patterns of schizophrenia using low dimensional embedding of fMRI. NeuroImage. 2010;49(4):3110–21.  https://doi.org/10.1016/j.neuroimage.2009.11.011.CrossRefPubMedGoogle Scholar
  112. 112.
    Venkataraman A, Whitford TJ, Westin CF, Golland P, Kubicki M. Whole brain resting state functional connectivity abnormalities in schizophrenia. Schizophr Res. 2012;139(1–3):7–12.  https://doi.org/10.1016/j.schres.2012.04.021.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Kambeitz J, Kambeitz-Ilankovic L, Leucht S, Wood S, Davatzikos C, Malchow B, Falkai P, Koutsouleris N. Detecting neuroimaging biomarkers for schizophrenia: a meta-analysis of multivariate pattern recognition studies. Neuropsychopharmacology. 2015;40(7):1742–51.  https://doi.org/10.1038/npp.2015.22.CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Koutsouleris N, Borgwardt S, Meisenzahl EM, Bottlender R, Moller HJ, Riecher-Rossler A. Disease prediction in the at-risk mental state for psychosis using neuroanatomical biomarkers: results from the FePsy study. Schizophr Bull. 2012;38(6):1234–46.  https://doi.org/10.1093/schbul/sbr145.CrossRefPubMedGoogle Scholar
  115. 115.
    Borgwardt S, Koutsouleris N, Aston J, Studerus E, Smieskova R, Riecher-Rossler A, Meisenzahl EM. Distinguishing prodromal from first-episode psychosis using neuroanatomical single-subject pattern recognition. Schizophr Bull. 2013;39(5):1105–14.  https://doi.org/10.1093/schbul/sbs095.CrossRefPubMedGoogle Scholar
  116. 116.
    Kambeitz-Ilankovic L, Meisenzahl EM, Cabral C, von Saldern S, Kambeitz J, Falkai P, Moller HJ, Reiser M, Koutsouleris N. Prediction of outcome in the psychosis prodrome using neuroanatomical pattern classification. Schizophr Res. 2016;173(3):159–65.  https://doi.org/10.1016/j.schres.2015.03.005.CrossRefPubMedGoogle Scholar
  117. 117.
    de Wit S, Ziermans TB, Nieuwenhuis M, Schothorst PF, van Engeland H, Kahn RS, Durston S, Schnack HG. Individual prediction of long-term outcome in adolescents at ultra-high risk for psychosis: applying machine learning techniques to brain imaging data. Hum Brain Mapp. 2017;38(2):704–14.  https://doi.org/10.1002/hbm.23410.CrossRefPubMedGoogle Scholar
  118. 118.
    Fusar-Poli P, Yung AR, McGorry P, van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. Psychol Med. 2014;44(1):17–24.  https://doi.org/10.1017/S0033291713000184.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Annarita Vignapiano
    • 1
  • Lynn E. DeLisi
    • 2
  • Silvana Galderisi
    • 1
  1. 1.Department of PsychiatryUniversity of Campania “Luigi Vanvitelli”NaplesItaly
  2. 2.VA Boston Healthcare SystemHarvard Medical SchoolBrocktonUSA

Personalised recommendations